Acadian Asset Management LLC Syndax Pharmaceuticals Inc Transaction History

Acadian Asset Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 12, 2020	SELL	$8.94 - $20.98 $109,970 - $258,074	-12,301 Closed	0 $0
Q1 2020 May 11, 2020	BUY	$6.65 - $12.03 $16,226 - $29,353	2,440 Added 24.74%	12,301 $135,000
Q4 2019 Feb 06, 2020	SELL	$5.43 - $9.22 $104,272 - $177,051	-19,203 Reduced 66.07%	9,861 $87,000
Q3 2019 Nov 07, 2019	BUY	$7.47 - $10.76 $63,935 - $92,094	8,559 Added 41.74%	29,064 $217,000
Q2 2019 Aug 08, 2019	BUY	$4.9 - $9.31 $100,474 - $190,901	20,505 New	20,505 $191,000

Q3 2018 Oct 30, 2018	SELL	$6.33 - $8.08 $18,755 - $23,941	-2,963 Closed	0 $0
Q2 2018 Jul 24, 2018	BUY	$6.93 - $14.63 $20,533 - $43,348	2,963 New	2,963 $21,000

197

90.1M

353K

207K

Ticker SNDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,565,200
Market Cap $1.39B
Description
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...

Get notified when there are updates to the investment portfolio of Acadian Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Acadian Asset Management LLC with notifications on news.